Veradermics’ Oral Hair Loss Drug Shows Strong Phase 2/3 Signal

Veradermics hair loss trial update

Veradermics’ (NYSE: MANE) lead candidate VDPHL01, an extended‑release oral minoxidil tablet, showed statistically significant hair growth versus placebo in men with mild‑to‑moderate male pattern baldness. The trial measured changes in non‑vellus (terminal) hair counts in a defined scalp area, a key clinical endpoint for androgenetic alopecia studies. This positive Phase 2/3 readout supports growing interest in Veradermics as a late‑stage hair loss stock.

 Non‑hormonal oral minoxidil formulation

VDPHL01 is a non‑hormonal, extended‑release oral minoxidil designed to smooth drug exposure over time. The goal is to stimulate hair follicles for scalp hair regrowth while reducing peak‑related cardiovascular side effect risks associated with standard oral minoxidil. This differentiated profile could make VDPHL01 an attractive option for patients who struggle with topical minoxidil adherence or limited results.

 Late‑stage hair loss pipeline

Veradermics is advancing a broader late‑stage clinical program in both men and women with pattern hair loss. Multiple Phase 2/3 and Phase 3 studies are designed to confirm efficacy, durability of response, and long‑term safety for VDPHL01. If successful, these trials could support future regulatory filings for a prescription oral treatment for androgenetic alopecia.

 Investor takeaway for hair loss stocks

For investors focused on hair loss stocks and dermatology biotech names, Veradermics’ VDPHL01 program highlights the potential of extended‑release oral minoxidil in a large, under‑served market. Continued progress in late‑stage trials, safety data, and competitive positioning versus other hair regrowth treatments will be key drivers of sentiment. This makes Veradermics a name to watch in the oral hair loss treatment space.